Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

huMNC2-CAR44 T cells

Next Previous
Drug Profile

huMNC2-CAR44 T cells

Alternative Names: CAR T therapeutics - Minerva; huMNC2-CAR44 T cells - Minerva Biotechnologies; huMNC2-scFv-CAR T cells; MUC1*-targeting CAR T cells

Latest Information Update: 28 Aug 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Minerva Biotechnologies
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Breast cancer
  • No development reported Solid tumours

Most Recent Events

  • 28 Aug 2024 No recent reports of development identified for preclinical development in Solid-tumours in USA (Parenteral)
  • 05 Apr 2024 Efficacy and adverse events data from a phase I portion of the phase I/II trial in Breast cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
  • 03 Aug 2022 huMNC2-CAR44 T cells is still in preclinical development for Solid tumours in USA (Minerva Biotechnologies pipeline, August 2022)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top